Accredited Investors Employee Shareholders Institutions Private Companies Who We Serve Trading and InvestingData SolutionsPrivate Asset Custody Institutional TradingForge ProTrade private companies with Forge’s institutional brokerage toolBrowse CompaniesIndividual InvestingForge MarketsFind new private company investment opportunitiesForge DataAnalyze private markets via Forge’s intuitive web applicationForge Private Market IndexMonitor a benchmark for actively traded private companies Forge Accuidity Private Market IndexInvest in an institutionally-managed diversified basket of private companies (QPs only)Self-Directed IRAForge TrustInvest in private companies and other alternative assets through a tax-advantaged Self-Directed IRASolutions All InsightsPrivate Market ReportsMarket InsightsBuying and Selling Pre-IPO All ReportsPrivate Market Updates Forge Investment OutlookStartup News and TrendsPrivate Market Data and AnalyticsTech IPO Calendar for 2024Private Market ExplainedBuying Pre-IPO SharesSelling Pre-IPO Shares Glossary Videos FAQsInsights About Us Leadership Investor Relations People & Culture Careers About

Ensoma Stock

Q: How to sell Ensoma stock?

If you hold private company shares of Ensoma - whether as an employee or an early investor - Forge can help you sell them. 1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have. 2. Indicate your interest to sell your Ensoma stock on our platform. 3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

www.ensoma.comHealthcare / BioTech & PharmaFounded: 2019Funding to Date: $163.05MM

Ensoma, founded in 2019, is a biotechnology company with the goal of expanding the reach of the curative power of genomic medicine by seeking to pioneer a next-generation in vivo approach using its Engenious vectors. Ensoma’s vectors are designed to deliver a diverse range of gene modification technologies without the need for stem cell collection or prior myeloablative conditioning (e.g., chemotherapy). As a result, Ensoma’s therapies aim to be delivered as a single injection in a diverse range of settings, including outpatient and settings where access to sophisticated healthcare systems may be limited. Ensoma is headquartered in Boston, Massachusetts.

Buy or sell Ensoma stockLearn more about Ensoma IPO

OverviewFinancingsValuation

Enterprise Value

Access Ensoma’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Ensoma.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Ensoma investors also invested in these private companies

Viking Global Investors

Credit Karma, AlphaSense, Lightmatter, Arctic Wolf, Ecovative Design, Apeel, Sionna Therapeutics, Human Immunology Biosciences, Iterable, Color

Takeda Ventures

Ensoma, Obsidian Therapeutics, Be Biopharma

Bill & Melinda Gates Foundation

Enko Chem, BlueWillow Biologics, Vedanta Biosciences, Ensoma

RIT Capital Partners

Kraken, Ensoma

F-Prime Capital

Neo4j, Carrot, Devoted Health, Icertis, Owkin, Ashby, Hone, TraceLink, Engrail Therapeutics, GoodData

Qatar Investment Authority

Insider, Eat Just, Ascend Elements, Swiggy, Celonis, Builder.ai, Starling Bank, Impact, Sionna Therapeutics, Ensoma

Mirae Asset Global Investments

Impossible Foods, MOLOCO, Ensoma, Unacademy, Septerna

Cormorant Asset Management

BioAge, Aardvark Therapeutics, Myra Vision, Alumis, FogPharma, Orionis Biosciences, Neurona Therapeutics, Ensoma, Supira Medical, Bigfoot Biomedical

Delos Capital

Zenas BioPharma, Cardurion Pharma, Ensoma, Instylla, Avenzo

Catalio Capital Management

Resilience, Freenome, FogPharma, Enveda Biosciences, NextPoint Therapeutics, Iambic Therapeutics, OnCusp Therapeutics, Ensoma, RefleXion Medical, Odyssey Therapeutics

SymBiosis Capital Management

Biosplice Therapeutics, Aardvark Therapeutics, FogPharma, Neurona Therapeutics, Ensoma, Endeavor BioMedicines, Saliogen Therapeutics

Arix Bioscience

Evommune, Ensoma

Bioluminescence Ventures

SURGE Therapeutics, Ensoma

Gilead Sciences

Ensoma

Solasta Ventures

Ensoma

5AM Ventures

Carmot Therapeutics, Ensoma

Alexandria Venture Investments

Element Biosciences, Ensoma, Invaio, Tr1x, Tome Biosciences, Asher Biotherapeutics, Lycia Therapeutics, Odyssey Therapeutics

Fred Hutchinson Cancer Research Center

Ensoma

Kite Pharma

Ensoma

Team

Management Team

Emile Nuwaysir Ph.D

Chief Executive Officer & President

Min Wang Ph.D

President & Chief Operating Officer

Daniel Leblanc

Chief Technology Officer

Robert Peters Ph.D

Chief Scientific Officer

Naina Bhasin Ph.D

Chief Business Officer

André Lieber Ph.D

Co-Founder & Scientific Advisor

Board Members

Kush Parmar Ph.D

5AM Ventures

Mark Chin

Arix Bioscience

Paula Soteropoulos

5AM Ventures

Stephen Knight MD

F-Prime Capital

Ensoma stock FAQs

Can you buy Ensoma stock?

As Ensoma is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Ensoma, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.

How to buy Ensoma stock?

To invest in a private company like Ensoma through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Ensoma stock?

Yes, you may be able to sell your Ensoma stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Ensoma stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Ensoma stock on our platform.
Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.

Is Ensoma a public company?

No, Ensoma is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Ensoma’s stock price?

Ensoma is a privately held company and therefore does not have a public stock price. However, you may access Ensoma’s private market stock price with Forge Data.

What is Ensoma’s stock ticker symbol?

Ensoma does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

CITYBIZ 05/17/2023

Kite Leads $50M Series B For Ensoma

Ensoma, a genomic medicines company developing one-time, in vivo treatments that precisely engineer any cell of the hematopoietic system, today announced the closing of an extension of its Series B financing by $50 million, bringing the total size of the funding round to $135 million.

BIOCENTURY 01/06/2023

In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition

The concept of in vivo cell therapies moves two steps ahead with the announcements that Ensoma raised $85 million in a series B financing round and added a Cas12a gene editing system to its toolbox through the acquisition of Twelve Bio.

Browse More Insights

Frequently Asked Questions

Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Ensoma Stock

Register To Buy and Sell Shares

Enterprise Value

Access Ensoma’s valuation and stock price.

Ensoma investors also invested in these private companies

Team

Management Team

Board Members

Ensoma stock FAQs

Can you buy Ensoma stock?

How to buy Ensoma stock?

Can you sell Ensoma stock?

How to sell Ensoma stock?

Is Ensoma a public company?

What is Ensoma’s stock price?

What is Ensoma’s stock ticker symbol?

Can institutional investors buy and sell private market stocks?

Other companies like Ensoma in the BioTech & Pharma sector

Kite Leads $50M Series B For Ensoma

In vivo cell therapy technology advances with Ensoma’s Twelve Bio acquisition

Frequently Asked Questions

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES